Palvella Therapeutics, Inc. (PVLA) stock
PVLANasdaqPharmaceutical PreparationsFiscal year ends December 31
$142.85−2.92 (-2.00%)
Close on Nov 20, 2026Market cap $2.06BP/E –Yield –
Palvella Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Palvella Therapeutics's free cash flow for the twelve months ending Sep 30, 2024 was $15.01M. For fiscal 2023 it was -$13.87M. The highest annual figure on record is $47.80M in fiscal 2017.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -$13.87M | – |
| FY2022 | Dec 31, 2022 | -$60.97M | – |
| FY2021 | Dec 31, 2021 | -$8.61M | – |
| FY2020 | Dec 31, 2020 | -$48.62M | – |
| FY2019 | Dec 31, 2019 | -$54.93M | – |
| FY2018 | Dec 31, 2018 | -$2.76M | -105.8% |
| FY2017 | Dec 31, 2017 | $47.80M | – |
| FY2016 | Dec 31, 2016 | -$14.95M | – |
| FY2015 | Dec 31, 2015 | -$13.33M | – |
| FY2014 | Dec 31, 2014 | -$5.33M | – |
| FY2013 | Dec 31, 2013 | -$3.13M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2024 | Sep 30, 2024 | -$2.74M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.60M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.10M | – |
| Q4 FY2023 | Dec 31, 2023 | $20.46M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.79M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.50M | – |
| Q1 FY2023 | Mar 31, 2023 | -$11.04M | – |
| Q4 FY2022 | Dec 31, 2022 | -$12.92M | – |
| Q3 FY2022 | Sep 30, 2022 | -$8.81M | – |
| Q2 FY2022 | Jun 30, 2022 | -$16.21M | -154.6% |
| Q1 FY2022 | Mar 31, 2022 | -$23.03M | – |
| Q4 FY2021 | Dec 31, 2021 | -$11.29M | – |
| Q3 FY2021 | Sep 30, 2021 | -$14.83M | – |
| Q2 FY2021 | Jun 30, 2021 | $29.68M | – |
| Q1 FY2021 | Mar 31, 2021 | -$12.17M | – |
| Q4 FY2020 | Dec 31, 2020 | -$14.00M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.73M | – |
| Q2 FY2020 | Jun 30, 2020 | -$10.84M | – |
| Q1 FY2020 | Mar 31, 2020 | -$17.06M | – |
| Q4 FY2019 | Dec 31, 2019 | -$15.15M | – |
| Q3 FY2019 | Sep 30, 2019 | -$12.88M | – |
| Q2 FY2019 | Jun 30, 2019 | -$11.67M | – |
| Q1 FY2019 | Mar 31, 2019 | -$15.23M | -149.2% |
| Q4 FY2018 | Dec 31, 2018 | -$9.62M | – |
| Q3 FY2018 | Sep 30, 2018 | -$14.68M | -142.1% |
| Q2 FY2018 | Jun 30, 2018 | -$9.38M | – |
| Q1 FY2018 | Mar 31, 2018 | $30.93M | +20.8% |
| Q4 FY2017 | Dec 31, 2017 | -$5.51M | – |
| Q3 FY2017 | Sep 30, 2017 | $34.91M | – |
| Q2 FY2017 | Jun 30, 2017 | -$7.19M | – |
| Q1 FY2017 | Mar 31, 2017 | $25.59M | – |
| Q4 FY2016 | Dec 31, 2016 | -$6.97M | – |
| Q3 FY2016 | Sep 30, 2016 | -$3.77M | – |
See a number that looks wrong?